Data from the clinical development of entrectinib, targeting NTRK and ROS mutations, readies the drug for its approval across tumors with NTRK fusions as well as for advanced NSCLC with ROS1 fusions.
Medscape Medical News
Data from the clinical development of entrectinib, targeting NTRK and ROS mutations, readies the drug for its approval across tumors with NTRK fusions as well as for advanced NSCLC with ROS1 fusions.
Medscape Medical News
